S'abonner

Prevalence and distribution of human papillomavirus genotypes in Chinese women between 1991 and 2016: A systematic review - 02/06/18

Doi : 10.1016/j.jinf.2018.02.008 
Hong-Lu Zhou a, Wei Zhang b, Can-Jing Zhang a, Song-Mei Wang c, Ya-Chen Duan d, Jin-Xia Wang a, Huan Yang e, , Xuan-Yi Wang a, ⁎⁎
a Key Laboratory Medical Molecular Virology, MoE/MoH, the Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China 
b Library of Fudan University, Shanghai, 200032, People's Republic of China 
c Laboratory of Molecular Biology, Training Center of Medical Experiments, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, People's Republic of China 
d Department of Gynecological Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, People's Republic of China 
e Center for Drug Evaluation, China Food and Drug Administration, Beijing, 100038, People's Republic of China 

Corresponding author. Center for Drug Evaluation, China Food and Drug Administration, A1 Fu Xing Rd, Beijing, People's Republic of China.Center for Drug EvaluationChina Food and Drug AdministrationA1 Fu Xing RdBeijingPeople's Republic of China⁎⁎Corresponding author. Key Laboratory of Medical Molecular Virology of MoE & MoH, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, 138 Yi Xue Yuan Rd. Shanghai, People's Republic of China.Key Laboratory of Medical Molecular Virology of MoE & MoHInstitutes of Biomedical SciencesShanghai Medical CollegeFudan University138 Yi Xue Yuan RdShanghaiPeople's Republic of China

Highlights

This is the latest analysis on China-specific distribution of carcinogenic HPV types.
A dozen of HPV vaccines utilized uneven types are being developed in China.
The top 10 types in Chinese ICC patients were HPV 16, 18, 58, 52, 33, 31, 55, 68, 53 and 45.
The prevalence of HPV infection peaked between 20 and 24 years with a rate of 24.3%.
The second peak of prevalence was observed among women aged 45–55 years in less developed regions.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Human papillomavirus (HPV) associated cervical cancer is one of the most common cancers and ranked as the eighth most common killer for Chinese women. A dozen of HPV vaccines are being developed in China without a solid China-specific distribution of carcinogenic HPV types, thus, we performed this systematic review to explore the China-specific spectrum of high-risk types causing cancer.

Methods

Studies on HPV infection among Chinese women were searched. All retrieved articles were screened and reviewed by a standardized algorithm. Distribution of carcinogenic HPV types and age-specific prevalence were analyzed using random-effects model.

Results

A total of 303 articles were included in the final analysis. The top 10 common HPV types detected in ICC patients, in descending order of frequency, were HPV 16 (62.5%), 18 (12.4%), 58 (8.6%), 52 (5.7%), 33 (4.6%), 31 (3.5%), 55 (2.4%), 68 (2.4%), 53 (2.2%) and 45 (2.0%) respectively. Similar spectrum was found in women with precancer. The prevalence of HPV infection peaked between 20 and 24 years with a rate of 24.3%, thereafter declined substantially and stabilized at middle-ages. Compared to women living in the developed provinces, the second peak was observed among women aged 45–55 years in less developed regions.

Conclusion

In general, the spectrum of HPV types in women with precancer/cancer and the pattern of age-specific prevalence were consistent with that of elsewhere worldwide. However, some distinguished characteristics could also be concluded, and these imprinting should be considered and integrated when developing vaccines and strategy for disease control in China.

Le texte complet de cet article est disponible en PDF.

Keywords : Human papillomavirus, Genotype, Prevalence, Systematic review, China


Plan


 Hong-Lu Zhou, Wei Zhang, Can-Jing Zhang, and Song-Mei Wang contributed equally.


© 2018  The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 76 - N° 6

P. 522-528 - juin 2018 Retour au numéro
Article précédent Article précédent
  • Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana
  • G. Villa, R.O. Phillips, C. Smith, A.J. Stockdale, A. Beloukas, L.T. Appiah, D. Chadwick, A. Ruggiero, F.S. Sarfo, F. Post, AM Geretti
| Article suivant Article suivant
  • Estimating the numbers of pregnant women infected with Zika virus and infants with congenital microcephaly in Colombia, 2015–2017
  • Alys Adamski, Jeanne Bertolli, Carlos Castañeda-Orjuela, Owen J. Devine, Michael A. Johansson, Maritza Adegnis Gonzalez Duarte, Sherry L. Farr, Sarah C. Tinker, Marcela Maria Mercado Reyes, Van T. Tong, Oscar Eduardo Pacheco Garcia, Diana Valencia, Diego Alberto Cuellar Ortiz, Margaret A. Honein, Denise J. Jamieson, Martha Lucía Ospina Martínez, Suzanne M. Gilboa

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.